Risk of CKD in Diabetic Patients With MAFLD
This cross-sectional study of 300 participants investigates the risk of chronic kidney disease (CKD) in individuals with metabolic dysfunction-associated fatty liver disease (MAFLD) and type 2 diabetes. By evaluating hepatic measurements and metabolic markers, the study aims to identify key risk factors for CKD in this population, contributing valuable insights to inform targeted interventions.
- EligibilityCriteria: Inclusion Criteria:  Type 2 diabetic patients Willing and agreed to be included in the study.  Exclusion Criteria:  Type 1 diabetic patients or non-diabetic patients. Patient with known glomerulonephritis. Patient with diagnosis of or clinical features that are suspicious for another systemic disease that commonly causes kidney disease (e.g., connective tissue disorders, HIV). Patient with evidence of alternative kidney disease like (Documented obstructive uropathy, etc.) Patient with history of kidney transplantation. Patient with end stage renal disease or on dialysis. Patients with active malignancy. Individuals with a history of hepatitis B surface antigen or hepatitis C antibody positivity. history of excessive alcohol consumption (⩾30 g/day in men and ⩾20 g/day in women) Decompensated liver cirrhosis. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: The study population for this study comprises individuals diagnosed with type 2 diabetes mellitus either with or without MAFLD. The MAFLD group will encompass individuals meeting standardized diagnostic criteria for MAFLD and having a confirmed diagnosis of type 2 diabetes. Participants with comorbidities, such as viral hepatitis, cirrhosis, and cancers, will be excluded to ensure a focused study population. The chosen sample size of 300 individuals will allow for a robust examination of the prevalence of chronic kidney disease and associated risk factors within this specific cohort. - SamplingMethod: Non-Probability Sample